FOR IMMEDIATE RELEASE
Contact: CutisPharma, Inc. Media Relations
Wilmington, MA (April 22, 2019)—In an effort to continually improve and provide better products and services tailored to meet your needs and the needs of your patients, CutisPharma, Inc. is conducting a short survey and seeking your important feedback. As a pharmacist, you play a critical role in the support of patient care and an ever-expanding role in medication therapy management. Therefore, we request that you click this link or complete the survey located at http://bit.ly/2KRvaKv. This should only take two minutes of your time.
Your opinion matters to us and will play a crucial part in how we align our growth objectives. We appreciate you taking time out of your day to provide this invaluable feedback.
CutisPharma, Inc., based in Wilmington, MA, is a privately held specialty pharmaceutical company that has been an innovator in the industry for over 20 years by providing solutions for pharmacists. CutisPharma’s FIRST Unit-of-Use Compounding Kits have benefited millions of patients who are unable to swallow conventional oral dosage forms such as tablets and capsules and whose needs are not served by other commercially available therapies. In April 2018, CutisPharma announced the launch of FIRVANQ® (vancomycin hydrochloride for oral solution), the only FDA-approved vancomycin oral liquid therapy for patients with Clostridium difficile-associated diarrhea. For more information, visit www.cutispharma.com, www.firvanq.com, or contact us at firstname.lastname@example.org.